APC anti-mouse NK-1.1 Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Mouse

Immunogen

NK-1⁺ cells from mouse spleen and bone marrow

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Preparation

The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.

Concentration

0.2 mg/ml

Storage & Handling

The NK-1.1 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser

Red Laser (633 nm)

Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation^1,2, complement-dependent cytotoxicity³, in vivo depletion^4,5,9,10, mediation of in vitro redirected lysis⁶, blocking of NK cell function⁷, induction of proliferation⁸, immunohistochemical staining of frozen sections¹¹, immunofluorescence microscopy¹¹, and spatial biology (IBEX)^16,17. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 108712).

Application References

(PubMed link indicates BioLegend citation)

1. Carlyle JR, et al. 1999. J. Immunol. 162:5917. (IP)
2. Sentman CL, et al. 1989. Hybridoma 8:605. (IP)
3. Koo GC, et al. 1984. Hybridoma 3:301. (Cyt)
4. Sentman CL, et al. 1989. J. Immunol. 142:1847. (Deplete)
5. Koo GC, et al. 1986. J. Immunol. 137:3742. (Deplete)
6. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
7. Kung SK, et al. 1999. J. Immunol. 162:5876. (Block)
8. Reichlin A, et al. 1998. Immunol. Cell Biol. 76:143.
9. Drobyski W, et al. 1996. Blood 87:5355. (Deplete)
10. Andoniou CE, et al. 2005. Nat. Immunol. 6:1011. (Deplete)
11. Kanwar JR, et al. 2001. J. Natl. Cancer Inst. 93:1541. (IHC, IF)
12. Kroemer A, et al. 2008. J. Immunol. 180:7818. PubMed
13. Kim JY, et al. 2009. Exp Mol Med. 30:288. PubMed
14. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
15. Lee H, et al. 2014. Invest Ophthalmol Vis Sci. 55:2885. PubMed
16. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
17. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed

Product Citations

1. Koyama M, et al. 2015. J Exp Med. 212: 1303 - 1321. PubMed
2. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
3. Zhao D, et al. 2021. Innate Immun. 27:533. PubMed
4. Hutter K, et al. 2022. Front Immunol. 13:967914. PubMed
5. Furrer R, et al. 2021. Sci Adv. 7:eabi4852. PubMed
6. Liu W, et al. 2020. Mol Ther Oncolytics. 17:350. PubMed
7. Alissafi T, et al. 2018. J Clin Invest. 128:3840. PubMed
8. van Vloten JP, et al. 2022. J Immunother Cancer. 10:. PubMed
9. Symeonidou V, et al. 2021. Cell Rep. 37:109900. PubMed
10. Afolabi LO, et al. 2021. Front Immunol. 12:701671. PubMed
11. Wilson RP, et al. 2019. PLoS Pathog. 15:e1007745. PubMed
12. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
13. Shen T, et al. 2019. Cell Death Discov. 5:123. PubMed
14. Zhang J, et al. 2021. MedComm (Beijing). 2:256. PubMed
15. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
16. Zhao J, et al. 2019. Nat Commun. 10:899. PubMed
17. Neumann AM et al. 2017. PloS one. 12(11):e0187330 . PubMed
18. Mirshahi F, et al. 2022. Cell Rep. 38:110454. PubMed
19. Sun SJ, et al. 2022. Commun Biol. 5:867. PubMed
20. Bangs DJ, et al. 2022. Cell Rep. 38:110266. PubMed
21. Liang Y, et al. 2020. J Immunol. 204:2984. PubMed
22. Chen WS, et al. 2021. Cell Rep. 37:109974. PubMed
23. Ohtsuki T, et al. 2016. J Virol. 90: 300 - 307. PubMed
24. Starkl P, et al. 2020. Immunity. 53(4):793-804.e9. PubMed
25. Molina-Sanchez P, et al. 2020. Gastroenterology. 2203:159. PubMed
26. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
27. Shi S, et al. 2020. Clin Cancer Res. 26:5990. PubMed
28. Papafragkos I, et al. 2022. Front Immunol. 13:889075. PubMed
29. Hoffman D, et al. 2021. Immunity. 54:2712. PubMed
30. Janakiram N, et al. 2016. Sci Rep. 6:37046. PubMed
31. Pan W et al. 2017. Immunity. 47(2):284-297 . PubMed
32. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
33. Bourn JR, et al. 2021. Cancer Lett. 503:75. PubMed
34. Hirata Y, et al. 2015. PLoS One. 10: 0141785. PubMed
35. Wei SC, et al. 2020. Cancer Discov. . PubMed
36. Dos Santos Dias L, et al. 2021. PLoS Pathog. e1009324:17. PubMed
37. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
38. Aegerter H, et al. 2020. Nat Immunol. 0.975694444. PubMed
39. Kotfis K, et al. 2020. British Journal of Pharmacology. 49(1):66-72. PubMed
40. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
41. Hernández–Santos N, et al. 2018. Cell Host Microbe. 1.313194444. PubMed
42. Haase C, et al. 2022. Nat Methods. 19:1622. PubMed
43. Guo L, et al. 2021. Front Immunol. 12:785457. PubMed
44. Zenker S, et al. 2014. J Immunol. 192:2830. PubMed
45. Ray A, et al. 2015. PLoS One. 10: 0137314. PubMed
46. Satoh M, et al. 2016. Sci Rep. 6:28473. PubMed
47. Lehmann M, et al. 2016. J Leukoc Biol. 99: 1057 - 1064. PubMed
48. Hutter K, et al. 2020. FEBS J. . PubMed
49. Xu J et al. 2018. Cell. 173(3):762-775 . PubMed
50. Progatzky F, et al. 2021. Nature. 599:125. PubMed
51. Textor A, et al. 2014. Cancer Res. 74:6769. PubMed
52. Zhang Y, et al. 2021. J Immunol Res. 2021:5599439. PubMed
53. Stotesbury C, et al. 2020. J Immunol. 204:1582. PubMed
54. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
55. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
56. Kim S, et al. 2021. Elife. 10:. PubMed
57. Dobson HE, et al. 2020. Mucosal Immunol. 0.901388889. PubMed
58. Lim S, et al. 2016. PLoS One. 11: 0155689. PubMed
59. Solaymani-Mohammadi S, et al. 2016. J Leukoc Biol. 99: 475 - 482. PubMed
60. Ballet R, et al. 2014. PLoS Pathog. 10:1004550. PubMed
61. Stifter SA, et al. 2019. Cell Rep. 29:3539. PubMed
62. Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
63. Yu X, et al. 2019. Nat Commun. 10:574. PubMed
64. Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed
65. Terhorst D, et al. 2015. J Immunol. 195: 4953 - 4961. PubMed
66. Melo-Silva CR, et al. 2021. PLOS Pathogens. 17(5):e1009593. PubMed
67. DiToro D, et al. 2020. Immunity. 650:52. PubMed
68. Tuong ZK, et al. 2021. iScience. 24:103326. PubMed
69. Yu H, et al. 2021. Front Oncol. 11:736882. PubMed
70. Wüthrich M, et al. 2021. MBio. 12:e0201821. PubMed
71. Kohn EM, et al. 2022. J Immunol. 208:1417. PubMed
72. Zhang P, et al. 2022. Nat Commun. 13:1588. PubMed
73. Nahrendorf W, et al. 2021. eLife. 10:00. PubMed
74. Tsuzuki S, et al. 2015. Int Immunol. 10.1093/intimm/dxv058. PubMed
75. Burgener SS, et al. 2019. Cell Rep. 27:3646. PubMed
76. Zhang H, et al. 2017. Immunol Cell Biol. 10.1038/icb.2017.11. PubMed
77. Schuler F, et al. 2017. Nat Commun. . 10.1038/s41467-017-01850-4. PubMed
78. Dhar P, et al. 2021. Commun Biol. 4:905. PubMed
79. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
80. Woodring T, et al. 2022. iScience. 25:104934. PubMed
81. Huang W, et al. 2014. J Leukoc Biol. 96:55. PubMed
82. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
83. Xu JL, et al. 2022. Front Pharmacol. 13:911663. PubMed
84. Yoshida H, et al. 2019. Cell. 176:897. PubMed
85. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
86. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
87. Pelly V, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.4. PubMed
88. Fleskens V, et al. 2019. Cell Rep. 26:3600. PubMed
89. Peng V, et al. 2022. Nat Immunol. 23:619. PubMed
90. Stotesbury C, et al. 2020. Aging Cell. 19:e13170. PubMed
91. Tomita T, et al. 2021. Nat Commun. 12:3655. PubMed
92. Zhang S, et al. 2016. PLoS Pathog. 12: 1005617. PubMed
93. Liu CF, et al. 2017. Front Immunol. 1.445833333. PubMed
94. Kujur W, et al. 2020. PLoS Pathog. 16:e1009132. PubMed
95. Gawish R, et al. 2022. Elife. 11:. PubMed
96. Nabekura T, et al. 2020. Immunity. 96:52. PubMed
97. Schmidts A, et al. 2020. J Immunother Cancer. 8:. PubMed
98. Hester AK, et al. 2022. Cell Rep. 38:110363. PubMed
99. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed

RRID

AB_313396 (BioLegend Cat. No. 108709)
AB_313397 (BioLegend Cat. No. 108710)

Antigen Details

Structure

NKR-P1 gene family

Distribution

NK and NK-T cells in the NK1.1 mouse strains (C57BL, FVB/N, NZB)

Function

NK cell activation, IFN-γ production, cytotoxic granule release

Cell Type

NK cells, NKT cells

Biology Area

Immunology, Innate Immunity

Antigen References

1. Lanier LL. 1997. Immunity 6:371.
2. Yokoyama WM, et al. 1993. Ann. Rev. Immunol. 11:613.
3. Koo GC, et al. 1986. J. Immunol. 137:3742.
4. Giorda R, et al. 1991. J. Immunol. 147:1701.

Gene ID

17059 View all products for this Gene ID

UniProt

View information about NK-1.1 on UniProt.org

Documentation

• Technical Data Sheet (pdf)
• Certificate of Analysis
• Safety Data Sheet

Reviews

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Related Pages & Pathways

Related FAQs

Other Formats

Certificate of Analysis